Jim Cramer's 4 stock ideas from JPMorgan Healthcare Conference
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech.
Stay updated with breaking news from Dave Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech.
Eli Lilly has no plans to ease up on R&D spending. Meanwhile, Danaher continues to await an 'inflection point,' while GE Healthcare touts its AI opportunity.
The latest catalyst for Eli Lilly is a corporate decision more common in the retail and entertainment industries, not pharmaceuticals.
Eli Lilly is marking a year of momentum as they continue into the final phases of testing and trials of its latest drug they say will help millions of people who struggle with obesity.
Eli Lilly priced its new weight-loss drug Zepbound 20% lower than competitor Wegovy, an unusual move in the pharmaceutical world.